Maryam Asgari
Concepts (538)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 99 | 2026 | 806 | 20.150 |
Why?
| | Carcinoma, Squamous Cell | 54 | 2024 | 628 | 12.720 |
Why?
| | Melanoma | 25 | 2026 | 765 | 4.190 |
Why?
| | Keratosis, Actinic | 9 | 2024 | 12 | 3.640 |
Why?
| | Dermatology | 12 | 2020 | 131 | 3.450 |
Why?
| | Psoriasis | 8 | 2023 | 110 | 2.550 |
Why?
| | Dermatologic Agents | 8 | 2019 | 69 | 2.500 |
Why?
| | Genetic Loci | 6 | 2020 | 273 | 2.080 |
Why?
| | Vitamin D | 10 | 2021 | 402 | 2.010 |
Why?
| | Neoplasms, Multiple Primary | 4 | 2019 | 57 | 1.900 |
Why?
| | Keratinocytes | 13 | 2020 | 190 | 1.870 |
Why?
| | Dermatitis, Atopic | 6 | 2023 | 319 | 1.860 |
Why?
| | California | 22 | 2018 | 475 | 1.820 |
Why?
| | Genetic Predisposition to Disease | 13 | 2022 | 2488 | 1.810 |
Why?
| | Risk Assessment | 21 | 2023 | 3712 | 1.590 |
Why?
| | Mohs Surgery | 5 | 2021 | 30 | 1.510 |
Why?
| | Transplant Recipients | 6 | 2021 | 177 | 1.430 |
Why?
| | Incidence | 23 | 2024 | 2936 | 1.320 |
Why?
| | Humans | 163 | 2026 | 146342 | 1.260 |
Why?
| | Risk Factors | 41 | 2026 | 10921 | 1.240 |
Why?
| | Cohort Studies | 30 | 2023 | 6077 | 1.210 |
Why?
| | Organ Transplantation | 7 | 2021 | 244 | 1.200 |
Why?
| | Aged | 63 | 2026 | 26432 | 1.180 |
Why?
| | Middle Aged | 69 | 2026 | 36619 | 1.170 |
Why?
| | Fluorouracil | 5 | 2023 | 231 | 1.130 |
Why?
| | Registries | 9 | 2026 | 2400 | 1.080 |
Why?
| | Polymorphism, Single Nucleotide | 12 | 2024 | 2240 | 1.060 |
Why?
| | Genome-Wide Association Study | 11 | 2024 | 1537 | 1.020 |
Why?
| | Male | 93 | 2026 | 73396 | 1.020 |
Why?
| | Aged, 80 and over | 31 | 2026 | 8391 | 1.010 |
Why?
| | Papillomaviridae | 4 | 2019 | 113 | 0.960 |
Why?
| | Biological Products | 3 | 2021 | 258 | 0.950 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 829 | 0.930 |
Why?
| | Female | 91 | 2026 | 79499 | 0.930 |
Why?
| | Needs Assessment | 6 | 2018 | 404 | 0.920 |
Why?
| | Health Services Needs and Demand | 3 | 2012 | 287 | 0.880 |
Why?
| | Dietary Supplements | 5 | 2014 | 587 | 0.880 |
Why?
| | Follow-Up Studies | 17 | 2020 | 5439 | 0.880 |
Why?
| | Carcinoma, Merkel Cell | 5 | 2016 | 16 | 0.850 |
Why?
| | Skin Pigmentation | 3 | 2020 | 44 | 0.850 |
Why?
| | Skin Diseases | 3 | 2023 | 144 | 0.820 |
Why?
| | Precision Medicine | 3 | 2022 | 462 | 0.790 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 344 | 0.780 |
Why?
| | Adult | 52 | 2024 | 41087 | 0.770 |
Why?
| | Delivery of Health Care | 4 | 2020 | 947 | 0.760 |
Why?
| | Sunlight | 4 | 2018 | 78 | 0.720 |
Why?
| | Retrospective Studies | 30 | 2023 | 17438 | 0.720 |
Why?
| | Sex Factors | 6 | 2019 | 2107 | 0.720 |
Why?
| | Evidence-Based Medicine | 3 | 2019 | 731 | 0.690 |
Why?
| | Carcinoma | 2 | 2020 | 225 | 0.670 |
Why?
| | Genetic Background | 1 | 2020 | 16 | 0.650 |
Why?
| | SEER Program | 3 | 2017 | 233 | 0.650 |
Why?
| | Mendelian Randomization Analysis | 1 | 2021 | 68 | 0.650 |
Why?
| | Hidradenitis Suppurativa | 1 | 2020 | 11 | 0.630 |
Why?
| | Calcineurin Inhibitors | 1 | 2020 | 67 | 0.630 |
Why?
| | Early Detection of Cancer | 3 | 2023 | 506 | 0.630 |
Why?
| | Valproic Acid | 1 | 2020 | 45 | 0.620 |
Why?
| | Drug Approval | 2 | 2019 | 94 | 0.590 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2020 | 80 | 0.590 |
Why?
| | Orphan Drug Production | 1 | 2019 | 5 | 0.590 |
Why?
| | Women, Working | 1 | 2019 | 11 | 0.590 |
Why?
| | Point-of-Care Systems | 1 | 2021 | 185 | 0.580 |
Why?
| | Antihypertensive Agents | 3 | 2018 | 519 | 0.570 |
Why?
| | Myotonic Dystrophy | 1 | 2019 | 10 | 0.570 |
Why?
| | HLA-DRB1 Chains | 1 | 2019 | 109 | 0.570 |
Why?
| | Managed Care Programs | 3 | 2017 | 137 | 0.570 |
Why?
| | Salaries and Fringe Benefits | 1 | 2019 | 57 | 0.570 |
Why?
| | Proportional Hazards Models | 9 | 2017 | 1331 | 0.570 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 91 | 0.560 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2020 | 219 | 0.550 |
Why?
| | Patient Care | 1 | 2019 | 120 | 0.550 |
Why?
| | Rare Diseases | 1 | 2019 | 117 | 0.550 |
Why?
| | Genes, MHC Class II | 1 | 2018 | 77 | 0.540 |
Why?
| | Photosensitizing Agents | 1 | 2018 | 42 | 0.540 |
Why?
| | Aminoquinolines | 1 | 2017 | 18 | 0.530 |
Why?
| | Vitamin D Deficiency | 3 | 2021 | 189 | 0.530 |
Why?
| | Sex Distribution | 6 | 2017 | 382 | 0.530 |
Why?
| | Physicians, Women | 1 | 2019 | 92 | 0.520 |
Why?
| | Databases, Factual | 8 | 2019 | 1493 | 0.520 |
Why?
| | Models, Statistical | 2 | 2019 | 669 | 0.520 |
Why?
| | Lentigo | 1 | 2017 | 6 | 0.520 |
Why?
| | Vitamins | 5 | 2021 | 183 | 0.520 |
Why?
| | Lithium | 1 | 2017 | 38 | 0.510 |
Why?
| | DNA Virus Infections | 1 | 2017 | 3 | 0.500 |
Why?
| | Haplotypes | 2 | 2018 | 506 | 0.500 |
Why?
| | Young Adult | 19 | 2023 | 14330 | 0.490 |
Why?
| | Electronic Health Records | 3 | 2021 | 1210 | 0.490 |
Why?
| | Lymph Node Excision | 2 | 2015 | 174 | 0.480 |
Why?
| | Interferon Regulatory Factors | 1 | 2016 | 45 | 0.470 |
Why?
| | Glucocorticoids | 1 | 2020 | 536 | 0.470 |
Why?
| | Patient Satisfaction | 2 | 2011 | 706 | 0.470 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 712 | 0.450 |
Why?
| | Genomics | 2 | 2019 | 853 | 0.450 |
Why?
| | Bacterial Infections | 1 | 2017 | 247 | 0.440 |
Why?
| | HLA Antigens | 1 | 2017 | 241 | 0.440 |
Why?
| | Mass Screening | 3 | 2023 | 1307 | 0.440 |
Why?
| | Prognosis | 13 | 2018 | 4351 | 0.440 |
Why?
| | Membrane Transport Proteins | 1 | 2016 | 154 | 0.440 |
Why?
| | Community Health Services | 1 | 2017 | 229 | 0.440 |
Why?
| | Opioid-Related Disorders | 2 | 2021 | 634 | 0.430 |
Why?
| | Research Design | 3 | 2019 | 1143 | 0.430 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 266 | 0.430 |
Why?
| | Antigens, Neoplasm | 1 | 2016 | 271 | 0.420 |
Why?
| | Quality of Health Care | 1 | 2019 | 702 | 0.420 |
Why?
| | Skin | 6 | 2022 | 701 | 0.420 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2014 | 20 | 0.410 |
Why?
| | Neoplasms, Second Primary | 1 | 2015 | 103 | 0.410 |
Why?
| | Biomedical Research | 2 | 2019 | 729 | 0.410 |
Why?
| | Herpes Zoster | 1 | 2018 | 318 | 0.410 |
Why?
| | Models, Biological | 2 | 2019 | 1761 | 0.400 |
Why?
| | United States | 19 | 2026 | 16136 | 0.400 |
Why?
| | Adenocarcinoma, Papillary | 1 | 2013 | 11 | 0.400 |
Why?
| | Quality Improvement | 3 | 2020 | 1354 | 0.400 |
Why?
| | Confidence Intervals | 6 | 2017 | 329 | 0.400 |
Why?
| | Odds Ratio | 7 | 2017 | 1077 | 0.390 |
Why?
| | Sirolimus | 1 | 2015 | 282 | 0.390 |
Why?
| | Arthritis, Psoriatic | 1 | 2013 | 15 | 0.380 |
Why?
| | Prevalence | 10 | 2025 | 2861 | 0.380 |
Why?
| | Population Surveillance | 1 | 2016 | 481 | 0.380 |
Why?
| | Carcinoma, Large Cell | 1 | 2013 | 17 | 0.380 |
Why?
| | Kidney Transplantation | 1 | 2019 | 735 | 0.370 |
Why?
| | Risk | 4 | 2019 | 920 | 0.370 |
Why?
| | Epidermis | 1 | 2012 | 72 | 0.360 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 92 | 0.360 |
Why?
| | Neuroectodermal Tumor, Melanotic | 1 | 2012 | 1 | 0.360 |
Why?
| | Age Distribution | 4 | 2017 | 399 | 0.360 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 992 | 0.360 |
Why?
| | Logistic Models | 7 | 2018 | 2126 | 0.360 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 1221 | 0.350 |
Why?
| | Carotenoids | 1 | 2012 | 47 | 0.350 |
Why?
| | Case-Control Studies | 8 | 2026 | 3647 | 0.350 |
Why?
| | Adolescent | 19 | 2023 | 22557 | 0.350 |
Why?
| | Vitamin A | 1 | 2012 | 60 | 0.350 |
Why?
| | Skin Aging | 1 | 2011 | 20 | 0.350 |
Why?
| | Lymph Nodes | 1 | 2014 | 511 | 0.340 |
Why?
| | Mitochondria | 1 | 2018 | 997 | 0.330 |
Why?
| | Hypertension | 3 | 2018 | 1272 | 0.330 |
Why?
| | Tea | 1 | 2011 | 17 | 0.330 |
Why?
| | Surgery, Plastic | 1 | 2011 | 53 | 0.330 |
Why?
| | Massachusetts | 3 | 2021 | 178 | 0.310 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 1160 | 0.310 |
Why?
| | Neoplasm Staging | 7 | 2023 | 1488 | 0.300 |
Why?
| | Contraceptives, Oral | 1 | 2010 | 37 | 0.300 |
Why?
| | Global Health | 3 | 2025 | 403 | 0.300 |
Why?
| | Age Factors | 6 | 2018 | 3347 | 0.300 |
Why?
| | HIV Infections | 2 | 2017 | 3215 | 0.300 |
Why?
| | United States Food and Drug Administration | 3 | 2019 | 208 | 0.290 |
Why?
| | Pemphigus | 2 | 2024 | 8 | 0.270 |
Why?
| | Vaccines | 2 | 2024 | 389 | 0.270 |
Why?
| | Disease Susceptibility | 2 | 2020 | 339 | 0.270 |
Why?
| | Sunbathing | 2 | 2018 | 16 | 0.270 |
Why?
| | Genetic Association Studies | 2 | 2019 | 379 | 0.260 |
Why?
| | Patient Participation | 1 | 2011 | 457 | 0.260 |
Why?
| | Anticholesteremic Agents | 1 | 2009 | 156 | 0.260 |
Why?
| | Enhancer Elements, Genetic | 2 | 2020 | 190 | 0.260 |
Why?
| | Administration, Topical | 2 | 2017 | 154 | 0.250 |
Why?
| | Education, Medical, Continuing | 3 | 2019 | 130 | 0.250 |
Why?
| | Comorbidity | 4 | 2018 | 1665 | 0.250 |
Why?
| | DNA, Viral | 2 | 2012 | 354 | 0.250 |
Why?
| | Polymorphism, Genetic | 3 | 2019 | 612 | 0.240 |
Why?
| | Hemangiosarcoma | 1 | 2007 | 27 | 0.240 |
Why?
| | Head Movements | 1 | 2007 | 38 | 0.240 |
Why?
| | Head and Neck Neoplasms | 2 | 2014 | 563 | 0.240 |
Why?
| | Reference Values | 3 | 2017 | 796 | 0.240 |
Why?
| | Practice Patterns, Physicians' | 4 | 2017 | 1408 | 0.240 |
Why?
| | Morbidity | 3 | 2016 | 319 | 0.240 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2006 | 15 | 0.230 |
Why?
| | Survival Rate | 5 | 2017 | 2092 | 0.230 |
Why?
| | Calcifediol | 2 | 2018 | 30 | 0.230 |
Why?
| | Antioxidants | 1 | 2009 | 544 | 0.230 |
Why?
| | Drug Costs | 2 | 2017 | 116 | 0.230 |
Why?
| | Papillomavirus Infections | 4 | 2019 | 345 | 0.230 |
Why?
| | Neoplasm Invasiveness | 3 | 2017 | 504 | 0.220 |
Why?
| | Testicular Hydrocele | 1 | 2025 | 3 | 0.220 |
Why?
| | Computational Biology | 2 | 2020 | 678 | 0.220 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2022 | 305 | 0.220 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 449 | 0.220 |
Why?
| | Prospective Studies | 8 | 2018 | 8123 | 0.220 |
Why?
| | Ultraviolet Rays | 4 | 2019 | 376 | 0.210 |
Why?
| | CD4 Lymphocyte Count | 2 | 2017 | 280 | 0.210 |
Why?
| | Nose | 1 | 2005 | 67 | 0.210 |
Why?
| | Infant, Premature, Diseases | 1 | 2006 | 113 | 0.210 |
Why?
| | Face | 3 | 2019 | 177 | 0.210 |
Why?
| | Treatment Outcome | 9 | 2023 | 11821 | 0.210 |
Why?
| | Pemphigoid, Bullous | 1 | 2024 | 6 | 0.210 |
Why?
| | Photochemotherapy | 2 | 2021 | 39 | 0.200 |
Why?
| | Fibrosarcoma | 1 | 2004 | 22 | 0.200 |
Why?
| | Surgical Flaps | 1 | 2005 | 140 | 0.200 |
Why?
| | Surveys and Questionnaires | 8 | 2018 | 6073 | 0.200 |
Why?
| | Molecular Sequence Annotation | 2 | 2020 | 110 | 0.200 |
Why?
| | Child, Preschool | 9 | 2025 | 11913 | 0.200 |
Why?
| | Eosinophilia | 1 | 2006 | 224 | 0.200 |
Why?
| | Severity of Illness Index | 4 | 2023 | 2921 | 0.190 |
Why?
| | Genotype | 3 | 2018 | 1879 | 0.190 |
Why?
| | Patient Selection | 3 | 2013 | 728 | 0.190 |
Why?
| | Feeding Behavior | 1 | 2009 | 692 | 0.190 |
Why?
| | Insurance Claim Review | 2 | 2015 | 87 | 0.180 |
Why?
| | Receptors, Calcitriol | 2 | 2012 | 54 | 0.180 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2022 | 3 | 0.180 |
Why?
| | Eczema | 1 | 2023 | 66 | 0.180 |
Why?
| | Disease Progression | 3 | 2020 | 2867 | 0.180 |
Why?
| | Health Maintenance Organizations | 2 | 2014 | 106 | 0.180 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1712 | 0.180 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 156 | 0.180 |
Why?
| | Blood Coagulation Disorders | 1 | 2004 | 190 | 0.170 |
Why?
| | Endorphins | 1 | 2021 | 9 | 0.170 |
Why?
| | Immunocompromised Host | 3 | 2019 | 201 | 0.170 |
Why?
| | Child | 12 | 2025 | 22693 | 0.170 |
Why?
| | Electronics | 1 | 2021 | 65 | 0.170 |
Why?
| | Ascorbic Acid | 1 | 2022 | 183 | 0.170 |
Why?
| | Rituximab | 1 | 2022 | 208 | 0.160 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 209 | 0.160 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 28 | 0.160 |
Why?
| | Multifactorial Inheritance | 2 | 2019 | 243 | 0.160 |
Why?
| | Internet | 2 | 2017 | 660 | 0.160 |
Why?
| | Wnt-5a Protein | 1 | 2020 | 25 | 0.160 |
Why?
| | Rheumatic Diseases | 1 | 2022 | 101 | 0.160 |
Why?
| | Causality | 1 | 2021 | 128 | 0.160 |
Why?
| | Quality of Life | 2 | 2017 | 3200 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 1224 | 0.160 |
Why?
| | Venous Thrombosis | 1 | 2022 | 199 | 0.160 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2020 | 74 | 0.160 |
Why?
| | Sensitivity and Specificity | 3 | 2015 | 1998 | 0.150 |
Why?
| | Pulmonary Embolism | 1 | 2022 | 246 | 0.150 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 447 | 0.150 |
Why?
| | Boston | 1 | 2020 | 90 | 0.150 |
Why?
| | Physicians, Primary Care | 2 | 2013 | 210 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2024 | 467 | 0.150 |
Why?
| | Data Curation | 1 | 2019 | 21 | 0.150 |
Why?
| | Xeroderma Pigmentosum | 1 | 2019 | 9 | 0.150 |
Why?
| | Biomarkers | 2 | 2017 | 4340 | 0.150 |
Why?
| | Histocompatibility Testing | 1 | 2019 | 124 | 0.150 |
Why?
| | Neoplasms | 4 | 2021 | 2954 | 0.150 |
Why?
| | Thymidine Phosphorylase | 1 | 1999 | 13 | 0.150 |
Why?
| | Antirheumatic Agents | 1 | 2022 | 309 | 0.140 |
Why?
| | Symbiosis | 1 | 2019 | 71 | 0.140 |
Why?
| | Parents | 2 | 2018 | 1394 | 0.140 |
Why?
| | Torso | 1 | 2019 | 36 | 0.140 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 78 | 0.140 |
Why?
| | Repressor Proteins | 1 | 2022 | 430 | 0.140 |
Why?
| | Gene-Environment Interaction | 1 | 2020 | 190 | 0.140 |
Why?
| | Health Care Surveys | 2 | 2017 | 541 | 0.140 |
Why?
| | Administration, Cutaneous | 1 | 2018 | 128 | 0.140 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 388 | 0.140 |
Why?
| | Biopsy | 3 | 2013 | 1075 | 0.140 |
Why?
| | Off-Label Use | 1 | 2018 | 50 | 0.140 |
Why?
| | Algorithms | 4 | 2016 | 1849 | 0.140 |
Why?
| | Survival Analysis | 3 | 2016 | 1378 | 0.140 |
Why?
| | Extremities | 1 | 2019 | 142 | 0.130 |
Why?
| | Policy | 1 | 2019 | 147 | 0.130 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 1512 | 0.130 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2017 | 7 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 2113 | 0.130 |
Why?
| | Head | 1 | 2019 | 125 | 0.130 |
Why?
| | Injections, Subcutaneous | 1 | 2018 | 170 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 970 | 0.130 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 171 | 0.130 |
Why?
| | Documentation | 1 | 2019 | 202 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 366 | 0.130 |
Why?
| | Splenic Rupture | 1 | 1997 | 5 | 0.130 |
Why?
| | Evidence-Based Practice | 1 | 2019 | 231 | 0.130 |
Why?
| | Infectious Mononucleosis | 1 | 1997 | 10 | 0.130 |
Why?
| | Ultraviolet Therapy | 1 | 2017 | 13 | 0.130 |
Why?
| | Cryosurgery | 2 | 2021 | 46 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 200 | 0.120 |
Why?
| | Merkel cell polyomavirus | 1 | 2016 | 4 | 0.120 |
Why?
| | Disease-Free Survival | 2 | 2016 | 778 | 0.120 |
Why?
| | Longitudinal Studies | 2 | 2018 | 3017 | 0.120 |
Why?
| | Drug Utilization | 1 | 2017 | 171 | 0.120 |
Why?
| | Tumor Virus Infections | 1 | 2016 | 51 | 0.120 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2016 | 23 | 0.120 |
Why?
| | Paraneoplastic Syndromes | 1 | 2016 | 14 | 0.120 |
Why?
| | Immunotherapy | 1 | 2021 | 671 | 0.120 |
Why?
| | Genotyping Techniques | 1 | 2016 | 74 | 0.120 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2017 | 100 | 0.120 |
Why?
| | Family | 2 | 2011 | 690 | 0.120 |
Why?
| | Immunity | 1 | 2017 | 141 | 0.120 |
Why?
| | Sunburn | 2 | 2018 | 26 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 314 | 0.120 |
Why?
| | Infant, Newborn | 4 | 2025 | 6460 | 0.120 |
Why?
| | Infant | 5 | 2025 | 10114 | 0.110 |
Why?
| | International Classification of Diseases | 2 | 2015 | 142 | 0.110 |
Why?
| | Aspergillus | 1 | 2015 | 18 | 0.110 |
Why?
| | Spondylitis, Ankylosing | 1 | 2016 | 43 | 0.110 |
Why?
| | Genetic Variation | 1 | 2021 | 996 | 0.110 |
Why?
| | Pharmaceutical Services | 1 | 2016 | 76 | 0.110 |
Why?
| | Spondylarthritis | 1 | 2016 | 50 | 0.110 |
Why?
| | Aspergillosis | 1 | 2015 | 24 | 0.110 |
Why?
| | Gene Frequency | 1 | 2017 | 496 | 0.110 |
Why?
| | Voriconazole | 1 | 2015 | 21 | 0.110 |
Why?
| | Linear Models | 1 | 2018 | 857 | 0.110 |
Why?
| | Intention | 1 | 2017 | 187 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2023 | 1408 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2016 | 496 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1591 | 0.110 |
Why?
| | Viral Load | 1 | 2017 | 526 | 0.110 |
Why?
| | Cause of Death | 1 | 2017 | 456 | 0.110 |
Why?
| | Sebaceous Glands | 1 | 2014 | 4 | 0.110 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2015 | 37 | 0.110 |
Why?
| | Kava | 1 | 2014 | 3 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1543 | 0.110 |
Why?
| | Fetal Blood | 1 | 2017 | 325 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2020 | 770 | 0.110 |
Why?
| | Drug Eruptions | 1 | 2014 | 28 | 0.110 |
Why?
| | Plant Preparations | 1 | 2014 | 37 | 0.100 |
Why?
| | Motivation | 1 | 2019 | 605 | 0.100 |
Why?
| | Surgeons | 1 | 2019 | 351 | 0.100 |
Why?
| | Phytotherapy | 1 | 2014 | 74 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1432 | 0.100 |
Why?
| | Body Mass Index | 2 | 2021 | 2458 | 0.100 |
Why?
| | Exanthema | 1 | 2014 | 86 | 0.100 |
Why?
| | Sex Characteristics | 1 | 2019 | 801 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1068 | 0.100 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2014 | 118 | 0.100 |
Why?
| | Health Personnel | 2 | 2017 | 754 | 0.100 |
Why?
| | Hand | 2 | 2026 | 157 | 0.100 |
Why?
| | Veterans | 1 | 2026 | 1650 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2020 | 881 | 0.100 |
Why?
| | Clinical Coding | 1 | 2013 | 28 | 0.100 |
Why?
| | Stomach Neoplasms | 1 | 2015 | 128 | 0.090 |
Why?
| | Systematized Nomenclature of Medicine | 1 | 2013 | 13 | 0.090 |
Why?
| | Animals | 7 | 2021 | 38107 | 0.090 |
Why?
| | Gastrectomy | 1 | 2015 | 164 | 0.090 |
Why?
| | Lip Neoplasms | 1 | 2012 | 2 | 0.090 |
Why?
| | Hydrochlorothiazide | 1 | 2012 | 7 | 0.090 |
Why?
| | Signal Transduction | 2 | 2019 | 5246 | 0.090 |
Why?
| | Nifedipine | 1 | 2012 | 27 | 0.090 |
Why?
| | Calcium, Dietary | 1 | 2012 | 52 | 0.090 |
Why?
| | Mutation | 3 | 2019 | 4093 | 0.090 |
Why?
| | Skin Transplantation | 2 | 2004 | 77 | 0.090 |
Why?
| | Sunscreening Agents | 1 | 2012 | 25 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 931 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1432 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 530 | 0.090 |
Why?
| | Arthritis, Juvenile | 1 | 2013 | 64 | 0.090 |
Why?
| | Methotrexate | 1 | 2013 | 234 | 0.090 |
Why?
| | Computer-Assisted Instruction | 1 | 2012 | 69 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1339 | 0.090 |
Why?
| | Genetic Testing | 2 | 2019 | 492 | 0.090 |
Why?
| | Mortality | 1 | 2015 | 375 | 0.090 |
Why?
| | Lung Transplantation | 1 | 2015 | 326 | 0.090 |
Why?
| | Professional Competence | 1 | 2012 | 90 | 0.090 |
Why?
| | Fees and Charges | 1 | 2011 | 12 | 0.090 |
Why?
| | Private Practice | 1 | 2011 | 17 | 0.090 |
Why?
| | Graft Rejection | 1 | 2015 | 516 | 0.090 |
Why?
| | Marital Status | 1 | 2011 | 47 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2007 | 1503 | 0.090 |
Why?
| | Electrosurgery | 1 | 2012 | 42 | 0.090 |
Why?
| | Food | 1 | 2012 | 149 | 0.090 |
Why?
| | Hedgehog Proteins | 1 | 2012 | 194 | 0.080 |
Why?
| | Nutrition Surveys | 1 | 2012 | 270 | 0.080 |
Why?
| | Basal Cell Nevus Syndrome | 1 | 2010 | 7 | 0.080 |
Why?
| | Homeodomain Proteins | 1 | 2015 | 525 | 0.080 |
Why?
| | Postoperative Hemorrhage | 1 | 2011 | 106 | 0.080 |
Why?
| | Program Development | 1 | 2012 | 371 | 0.080 |
Why?
| | Physicians | 1 | 2019 | 955 | 0.080 |
Why?
| | Immune Tolerance | 1 | 2012 | 386 | 0.080 |
Why?
| | Neoplasms, Basal Cell | 1 | 2009 | 4 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1079 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2023 | 2418 | 0.080 |
Why?
| | Family Relations | 1 | 2010 | 87 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1107 | 0.080 |
Why?
| | DNA Damage | 1 | 2012 | 439 | 0.070 |
Why?
| | Aspirin | 1 | 2013 | 405 | 0.070 |
Why?
| | Education, Medical | 1 | 2012 | 274 | 0.070 |
Why?
| | Faculty, Medical | 1 | 2012 | 309 | 0.070 |
Why?
| | Genetic Counseling | 1 | 2009 | 82 | 0.070 |
Why?
| | Life Style | 1 | 2012 | 496 | 0.070 |
Why?
| | Eggs | 1 | 2009 | 24 | 0.070 |
Why?
| | Phylogeny | 2 | 2015 | 924 | 0.070 |
Why?
| | Behavior Therapy | 1 | 2011 | 291 | 0.070 |
Why?
| | Northwestern United States | 1 | 2008 | 56 | 0.070 |
Why?
| | Fishes | 1 | 2009 | 111 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2675 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 5899 | 0.070 |
Why?
| | Milk | 1 | 2009 | 117 | 0.070 |
Why?
| | Cervix Uteri | 1 | 2007 | 50 | 0.060 |
Why?
| | Time Factors | 3 | 2017 | 7109 | 0.060 |
Why?
| | Health Behavior | 2 | 2017 | 802 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 972 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2015 | 927 | 0.060 |
Why?
| | Energy Metabolism | 1 | 2013 | 930 | 0.060 |
Why?
| | Head-Down Tilt | 1 | 2007 | 6 | 0.060 |
Why?
| | Disclosure | 1 | 2007 | 91 | 0.060 |
Why?
| | Risk Reduction Behavior | 1 | 2009 | 220 | 0.060 |
Why?
| | Psychological Theory | 1 | 2007 | 95 | 0.060 |
Why?
| | Torsion Abnormality | 1 | 2007 | 22 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2015 | 1185 | 0.060 |
Why?
| | Eccrine Glands | 1 | 2006 | 2 | 0.060 |
Why?
| | Sweat Gland Diseases | 1 | 2006 | 2 | 0.060 |
Why?
| | Eosinophil-Derived Neurotoxin | 1 | 2006 | 3 | 0.060 |
Why?
| | Mupirocin | 1 | 2006 | 7 | 0.060 |
Why?
| | Eosinophil Major Basic Protein | 1 | 2006 | 7 | 0.060 |
Why?
| | Hamartoma | 1 | 2006 | 29 | 0.060 |
Why?
| | Arteriovenous Malformations | 1 | 2006 | 34 | 0.060 |
Why?
| | Bandages | 1 | 2006 | 38 | 0.060 |
Why?
| | Acetaminophen | 1 | 2008 | 268 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 138 | 0.050 |
Why?
| | Environmental Exposure | 1 | 2009 | 578 | 0.050 |
Why?
| | Clinical Competence | 1 | 2013 | 1272 | 0.050 |
Why?
| | Postoperative Complications | 2 | 2015 | 3034 | 0.050 |
Why?
| | Primary Health Care | 2 | 2017 | 1776 | 0.050 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 76 | 0.050 |
Why?
| | Necrosis | 1 | 2005 | 243 | 0.050 |
Why?
| | Cyclooxygenase 2 | 1 | 2004 | 166 | 0.050 |
Why?
| | Patient-Centered Care | 1 | 2009 | 553 | 0.050 |
Why?
| | Communication | 1 | 2010 | 980 | 0.050 |
Why?
| | Isoenzymes | 1 | 2004 | 294 | 0.050 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1942 | 0.050 |
Why?
| | Vaccination | 2 | 2023 | 1449 | 0.050 |
Why?
| | New York | 1 | 2023 | 128 | 0.050 |
Why?
| | Societies, Medical | 2 | 2018 | 907 | 0.050 |
Why?
| | Mucous Membrane | 1 | 2023 | 130 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2021 | 1327 | 0.050 |
Why?
| | Public Health | 1 | 2007 | 574 | 0.050 |
Why?
| | Surgical Mesh | 1 | 2002 | 54 | 0.040 |
Why?
| | Diclofenac | 1 | 2021 | 14 | 0.040 |
Why?
| | Infant, Premature | 1 | 2006 | 622 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2004 | 486 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1271 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 678 | 0.040 |
Why?
| | Delphi Technique | 1 | 2021 | 350 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 245 | 0.040 |
Why?
| | Hair Follicle | 1 | 1999 | 35 | 0.040 |
Why?
| | Hospitalization | 2 | 2023 | 2475 | 0.040 |
Why?
| | Ipilimumab | 1 | 2019 | 44 | 0.040 |
Why?
| | Cell Size | 1 | 1999 | 95 | 0.040 |
Why?
| | Antibody Specificity | 1 | 1999 | 181 | 0.040 |
Why?
| | Immunoenzyme Techniques | 1 | 1999 | 197 | 0.040 |
Why?
| | Oncogenes | 1 | 2019 | 113 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2004 | 1130 | 0.030 |
Why?
| | Lung Diseases, Obstructive | 1 | 1998 | 43 | 0.030 |
Why?
| | Keratoacanthoma | 1 | 2017 | 2 | 0.030 |
Why?
| | Photosensitivity Disorders | 1 | 2017 | 8 | 0.030 |
Why?
| | Urban Health | 1 | 1998 | 95 | 0.030 |
Why?
| | Rural Health | 1 | 1998 | 87 | 0.030 |
Why?
| | PUVA Therapy | 1 | 1997 | 6 | 0.030 |
Why?
| | Capecitabine | 1 | 2017 | 56 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2019 | 226 | 0.030 |
Why?
| | Retinoids | 1 | 2017 | 34 | 0.030 |
Why?
| | Risk Adjustment | 1 | 2018 | 86 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 1999 | 882 | 0.030 |
Why?
| | Vitamin B Complex | 1 | 2017 | 39 | 0.030 |
Why?
| | Reimbursement Mechanisms | 1 | 2018 | 79 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2018 | 239 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 133 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2017 | 108 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 222 | 0.030 |
Why?
| | Splenectomy | 1 | 1997 | 61 | 0.030 |
Why?
| | Niacinamide | 1 | 2017 | 103 | 0.030 |
Why?
| | Primary Prevention | 1 | 2018 | 222 | 0.030 |
Why?
| | Pregnancy Trimester, Second | 1 | 2017 | 91 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 314 | 0.030 |
Why?
| | Rheumatologists | 1 | 2016 | 15 | 0.030 |
Why?
| | Decision Making | 1 | 2024 | 993 | 0.030 |
Why?
| | Computers | 1 | 2016 | 66 | 0.030 |
Why?
| | Pregnancy Trimester, First | 1 | 2017 | 140 | 0.030 |
Why?
| | Drugs, Generic | 1 | 2016 | 28 | 0.030 |
Why?
| | Sampling Studies | 1 | 2016 | 97 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2016 | 183 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 1998 | 543 | 0.030 |
Why?
| | Visual Pathways | 1 | 1996 | 61 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2001 | 1064 | 0.030 |
Why?
| | Medical Records Systems, Computerized | 1 | 2016 | 95 | 0.030 |
Why?
| | Developing Countries | 1 | 1998 | 312 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 334 | 0.030 |
Why?
| | Pattern Recognition, Visual | 1 | 1996 | 105 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 693 | 0.030 |
Why?
| | Research | 1 | 2018 | 421 | 0.030 |
Why?
| | Photic Stimulation | 1 | 1996 | 265 | 0.030 |
Why?
| | Pharmacoepidemiology | 1 | 2015 | 24 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1463 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 693 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1707 | 0.030 |
Why?
| | Erythema | 1 | 2014 | 28 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2015 | 153 | 0.030 |
Why?
| | Health Expenditures | 1 | 2016 | 198 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 651 | 0.030 |
Why?
| | Prenatal Care | 1 | 2017 | 310 | 0.030 |
Why?
| | Mice | 3 | 2021 | 18297 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1998 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2015 | 180 | 0.020 |
Why?
| | Papillomavirus Vaccines | 1 | 2017 | 296 | 0.020 |
Why?
| | Air Pollutants | 1 | 1998 | 406 | 0.020 |
Why?
| | Phototherapy | 1 | 2013 | 49 | 0.020 |
Why?
| | Infliximab | 1 | 2013 | 107 | 0.020 |
Why?
| | Computer User Training | 1 | 2012 | 5 | 0.020 |
Why?
| | Graft Survival | 1 | 2015 | 523 | 0.020 |
Why?
| | Medicaid | 1 | 2016 | 477 | 0.020 |
Why?
| | Codon | 1 | 2012 | 92 | 0.020 |
Why?
| | Washington | 1 | 2012 | 157 | 0.020 |
Why?
| | Ibuprofen | 1 | 2012 | 87 | 0.020 |
Why?
| | Postmenopause | 1 | 2013 | 394 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2015 | 1135 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3416 | 0.020 |
Why?
| | Medicare | 1 | 2016 | 920 | 0.020 |
Why?
| | Regression Analysis | 1 | 2012 | 999 | 0.020 |
Why?
| | Histoplasmosis | 1 | 1970 | 15 | 0.020 |
Why?
| | Coccidioidomycosis | 1 | 1970 | 8 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2011 | 251 | 0.020 |
Why?
| | Skin Tests | 1 | 1970 | 94 | 0.020 |
Why?
| | Michigan | 1 | 2009 | 203 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 203 | 0.020 |
Why?
| | Lipids | 1 | 2013 | 714 | 0.020 |
Why?
| | Papanicolaou Test | 1 | 2007 | 35 | 0.020 |
Why?
| | Health Surveys | 1 | 1970 | 511 | 0.020 |
Why?
| | Vaginal Smears | 1 | 2007 | 54 | 0.020 |
Why?
| | Psychology | 1 | 2007 | 85 | 0.020 |
Why?
| | Blood Pressure | 1 | 2013 | 1765 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2007 | 162 | 0.010 |
Why?
| | Iran | 2 | 1998 | 39 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1763 | 0.010 |
Why?
| | Pregnancy | 1 | 2017 | 7230 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 1996 | 3926 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2012 | 874 | 0.010 |
Why?
| | Blood Glucose | 1 | 2013 | 2360 | 0.010 |
Why?
| | Varicose Ulcer | 1 | 2002 | 5 | 0.010 |
Why?
| | Diabetic Foot | 1 | 2002 | 25 | 0.010 |
Why?
| | Wound Healing | 1 | 2002 | 354 | 0.010 |
Why?
| | Sulfur Oxides | 1 | 1998 | 1 | 0.010 |
Why?
| | Nitrogen Oxides | 1 | 1998 | 46 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1997 | 26 | 0.010 |
Why?
| | Spirometry | 1 | 1998 | 234 | 0.010 |
Why?
| | Visual Cortex | 1 | 1996 | 84 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1997 | 1031 | 0.010 |
Why?
| | Brain Mapping | 1 | 1996 | 541 | 0.010 |
Why?
| | Histoplasmin | 1 | 1970 | 1 | 0.000 |
Why?
| | Mass Chest X-Ray | 1 | 1970 | 4 | 0.000 |
Why?
| | Coccidioides | 1 | 1970 | 7 | 0.000 |
Why?
| | Histoplasma | 1 | 1970 | 11 | 0.000 |
Why?
| | Blood Cell Count | 1 | 1970 | 56 | 0.000 |
Why?
| | Tuberculin Test | 1 | 1970 | 36 | 0.000 |
Why?
| | Occupations | 1 | 1970 | 50 | 0.000 |
Why?
| | Climate | 1 | 1970 | 79 | 0.000 |
Why?
| | Soil Microbiology | 1 | 1970 | 115 | 0.000 |
Why?
| | Antigens | 1 | 1970 | 350 | 0.000 |
Why?
| | Sputum | 1 | 1970 | 302 | 0.000 |
Why?
| | Rural Population | 1 | 1970 | 677 | 0.000 |
Why?
|
|
Asgari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|